I went into these results expecting a catch, and the headline number refused to give me one. The trial randomized adults aged 18 to 45 with type 2 diabetes, and 27 of 50 who went through an intensive diet-and-exercise program were in remission at 24 weeks. Remission meant an HbA1c under 6.5 percent, the same line doctors use to diagnose diabetes, with no glucose-lowering medication for at least 12 weeks. On usual care, 2 of 46 got there. That’s 54 percent against 4 percent, in the age group whose disease is supposed to be the hardest to shift.

IN REMISSION AT 24 WEEKS
27 of 50 program participants in remission
Figure data
MeasurePartWhole
program participants in remission2750
On usual care, 2 of 46 reached remission. Source: ScienceDaily: Type 2 diabetes breakthrough as 54% achieve remission in just 6 months (2026)

The trial is called RESET for Remission. It was published in The Lancet Regional Health – Americas and presented at this fall’s European Association for the Study of Diabetes meeting. Researchers at the University of Leicester, McGill University and the University of Alberta ran it. The average participant was 38 with a BMI of 35.2, and nobody was on insulin. All of them had been diagnosed within the previous six years. Young-onset type 2 is not a milder version of the disease. The investigators’ own protocol says so directly: “Compared with later-onset T2DM and even type 1 diabetes, young-onset T2DM has a more aggressive phenotype.” A Cambridge and Glasgow analysis of 1.5 million people in The Lancet Diabetes & Endocrinology estimated that Americans diagnosed at 30 die about 14 years earlier than people without diabetes, and those diagnosed at 40 die about 10 years earlier. So the question I kept turning over was a blunt one. If a structured program can do this for people in their thirties, why does a newly diagnosed 38-year-old have to find it in a journal?

DIAGNOSED AT 30
14 yearsearlier death, US estimate
Estimated life lost for Americans diagnosed with type 2 diabetes at age 30. Source: ScienceDaily: Type 2 diabetes diagnosis at age 30 can reduce life expectancy by up to 14 years (2023)

The program was hard work, and that’s the reason it deserves a place in clinics. Participants stopped their glucose-lowering drugs for the first 12 weeks while eating 800 to 900 calories a day. The protocol also called for halting most blood pressure pills at the start, except ACE inhibitors or ARBs prescribed because the kidneys were leaking protein, and it set glucose and blood-pressure thresholds for restarting medication. For the first two weeks, every calorie came from a formula product; the protocol specifies Nestlé’s Optifast line. From week three, one ordinary meal a day came back, with targets for protein, fruit and vegetables, and an exercise physiologist ran two supervised sessions a week mixing aerobic and resistance training, with a third session done on their own. After week 12 a weight-maintenance diet took over and the independent exercise continued. Three months of a calorie ceiling, a trainer and blood-sugar checks is a lot more than “eat better and move more,” and nobody should pretend a pamphlet replicates it.

I’d expected the maintenance stretch to leak, because that’s when the pull back toward old habits starts. At the group level, it barely did: remission was 58 percent at the end of the low-energy phase and 54 percent after the maintenance phase. Those are rates for the whole arm, so they don’t prove that every individual who crossed the line stayed there, but the arm didn’t slide. The count is conservative, too. Of the 96 people randomized, 86 (90 percent) completed the final assessment, and anyone with missing data was counted as not in remission.

Wait, though. Why would these patients, of all people, respond this well? The body scans offer a clue. Average weight fell from 100.7 to 92.3 kilograms, about 18 pounds, and Healio’s report lists where it came from relative to usual care: a 16.5 percent greater drop in fat mass, larger declines in abdominal and thigh fat, and greater reductions in liver fat and the pancreatic fat fraction. The liver stores and releases glucose. The pancreas makes the insulin that tells it when to stop. Fat sitting in both is one leading explanation for how type 2 diabetes takes hold, so watching it drain from exactly those two organs alongside remission is hard to ignore, though the trial measured the two together and didn’t prove one caused the other. Co-lead Thomas Yates told Healio, “We got reductions in visceral and hepatic adiposity that are comparable to obesity medications.” Meanwhile fat-free mass and muscle volume were similar between the groups, handgrip strength rose 7.6 percent more than with usual care, and cardiorespiratory fitness rose 10.3 percent more. I’d assumed a diet this lean would cost people muscle. It didn’t show up here. There was no diet-only arm, though, so nobody can say how much of the remission or the strength came from the weight room and how much from the calorie cut.

VERSUS USUAL CARE AT 24 WEEKS
16.5%
greater drop in fat mass
7.6%
greater gain in grip strength
10.3%
greater gain in aerobic fitness
Fat-free mass and muscle volume were similar between the two groups. Source: Healio: Low-energy diet plus exercise could help adults with type 2 diabetes achieve remission (EASD 2026)

The press coverage pushed the size of the effect further than the data can carry. ScienceDaily wrote that participants were “21 times more likely” to reach remission. That’s an adjusted odds ratio of 21.6, and its 95 percent confidence interval runs from 6.2 to 114.5. An interval that wide is what 96 people buys you. The plainer number holds up better and is still enormous: a 50-percentage-point absolute difference.

ADJUSTED ODDS OF REMISSION (OR)
Figure data
ResultValue (OR)Lower boundUpper bound
Program vs usual care21.66.2114.5
With only 96 people randomized, the interval is very wide. Source: Medical Dialogues: Low energy diet plus supervised exercise tied to early-onset type 2 diabetes remission

Durability is where this approach has been tested before. The UK’s DiRECT trial, funded by Diabetes UK, used a similar formula-diet approach and put 46 percent of participants into remission at one year and 36 percent at two. By year five, 13 percent of those with five-year data were still in remission, and some people regained notable weight, especially through year three. The intervention group as a whole also had fewer than half the illnesses needing hospital admission, 4.8 versus 10.2 events per 100 patient-years. RESET stops at six months, so it can’t tell us whether young patients hold on better or worse than DiRECT’s older ones did.

RESET has other gaps. It was open-label, although outcome assessment was blinded. The program group got far more contact with researchers than usual care did, adherence to diet and exercise was measured imprecisely, and the selected population may not represent everyone with young-onset diabetes. The early weeks were rough: 43 of the 50 program participants reported at least one adverse event, against 6 of the 46 on usual care, mostly constipation, headaches, dizziness and fatigue from the diet, which generally resolved. There were no serious adverse events.

Then there’s who ran it. The protocol lists public money from the UK Medical Research Council and the Canadian Institutes of Health Research, plus the John R McConnell Foundation and the NIHR Leicester Biomedical Research Centre, with Roche Diabetes Care and Dexcom supplying glucose-monitoring materials. Yates reports funding from Abbott and Biomea Fusion and consulting for Regeneron. Protocol co-authors Kamlesh Khunti and Melanie Davies list honoraria or grants from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi and Janssen, the companies whose diabetes and weight-loss drugs dominate this market. Even with those ties around the table, the result points away from the prescription pad. A program built on dietitians, exercise physiologists and months of supervision has no sales force behind it, and that’s exactly why eligible young patients should be offered it as a matter of routine instead of discovering it by accident.

If I were 38, freshly diagnosed and not on insulin, I would ask my doctor for a supervised program like this one right away, and I’d get my HbA1c checked every few months after it ended, because six months is all this trial can vouch for.

Sources

  1. The Lancet Regional Health – Americas: RESET for Remission randomized trial (2026)
  2. Healio: Low-energy diet plus exercise could help adults with type 2 diabetes achieve remission (EASD 2026)
  3. ScienceDaily: Type 2 diabetes breakthrough as 54% achieve remission in just 6 months (2026)
  4. Medical Dialogues: Low energy diet plus supervised exercise tied to early-onset type 2 diabetes remission
  5. BMJ Open: RESET for REMISSION randomized controlled trial protocol (2022)
  6. University of Glasgow: DiRECT five-year extension results (2024)
  7. ScienceDaily: Type 2 diabetes diagnosis at age 30 can reduce life expectancy by up to 14 years (2023)